Application of germacrone in preparation of product for preventing and treating post-traumatic stress disorder

By using gemmatone to relieve post-traumatic stress disorder, the existing PTSD treatment has been solved, and the problems of limited efficacy and major side effects have been significantly improved, anxiety, depression-like behavior and hippocampal tissue abnormalities have been improved, and the serum 5-HT content has been improved, achieving Effective treatment of post-traumatic stress disorder.

CN118986945APending Publication Date: 2024-11-22ACADEMY OF MILITARY MEDICAL SCIENCES
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411426634.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-12
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The current drugs for treating post-traumatic stress disorder (PTSD) have limited efficacy, have large side effects and single targets, and lack safe and efficient treatment plans.

Method used

Germacrone is used as an active ingredient to relieve anxiety-like behavior, depression-like behavior and learning and memory dysfunction, inhibit HT22 cell damage, increase serum 5-HT content, improve neuronal cell abnormalities in hippocampal tissue, and prepare for prevention and treatment of post-trauma Products for stress disorder.

Benefits of technology

Gematone significantly improved cell viability and cell damage in hippocampal neurons in in vitro stress models, reversed nuclear area reduction and increased nuclear density, reduced ROS and MMP abnormalities, significantly improved PTSD-like behavior and serum 5-HT The content level has significant anti-stress damage and anti-PTSD effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118986945A_ABST
    Figure CN118986945A_ABST
Patent Text Reader

Abstract

The invention provides application of germacrone in preparation of a product for preventing and treating post-traumatic stress disorder, and belongs to the technical field of medicines. It is indicated for the first time that germacrone can remarkably improve HT22 cell activity decline caused by CORT, meanwhile, nuclear area reduction of HT22 cells in an in-vitro stress model and the phenomenon that nuclear density, ROS level and MMP are remarkably abnormal are reversed, and the germacrone has a remarkable stress injury resisting effect. Moreover, the germacrone can also significantly improve the PTSD-like behavior of the SPS mouse, improve the serum 5-HT content level of the SPS mouse and the pathological abnormality of hippocampus, and has a significant anti-PTSD effect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical technology, and in particular relates to the application of germacrone in preparing products for preventing and treating post-traumatic stress disorder. Background Art

[0002] Post-traumatic stress disorder (PTSD) is a chronic traumatic mental disorder that occurs after exposure to severe traumatic events. People's understanding of PTSD is relatively late, and the research on its pathogenesis and treatment drugs is relatively lagging. Its pathogenesis is still unclear, and there is a lack of safe and effective treatment drugs. Currently, the first-line treatment drugs for PTSD are mainly selective serotonin (5-HT) reuptake inhibitors, which have significant efficacy, but have many shortcomings such as large side effects, single ingredients, and single targets. Germacrone (GM, molecular formula: C 15 H 22 O, molecular weight: 218.17) is a sesquiterpenoid compound, mainly extracted from Curcuma wenyujin, Curcuma guangxiensis or Curcuma pengshu, and Germacron is also a quality marker of the above Chinese medicines. Germacron has a high pharmacological effect, but there is no relevant report on whether Germacron can be used to treat PRSD and its therapeutic mechanism. Summary of the invention

[0003] In view of this, the object of the present invention is to provide the use of germacrone in the preparation of products for preventing and treating post-traumatic stress disorder.

[0004] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0005] The invention provides application of germacrone in preparing products for preventing and treating post-traumatic stress disorder.

[0006] Preferably, the germacron relieves anxiety-like behaviors, depression-like behaviors and learning and memory dysfunction caused by post-traumatic stress disorder.

[0007] Preferably, the germacone inhibits HT22 cell damage.

[0008] Preferably, the germacron achieves any one or more of increasing the nuclear area of ​​HT22 cells, reducing the nuclear density of HT22 cells, reducing the abnormal increase of ROS in HT22 cells, and reducing the abnormal increase of MMP in HT22 cells.

[0009] Preferably, the germacron increases the 5-HT content in serum.

[0010] Preferably, the germacron improves abnormalities of neuronal cells in hippocampal tissue.

[0011] Preferably, the product comprises a medicine.

[0012] Preferably, the active ingredient of the drug includes germacrone.

[0013] Preferably, the weight proportion of germacrone in the drug is 0.01%-99%.

[0014] Preferably, the drug is added with pharmaceutically acceptable excipients.

[0015] Compared with the prior art, the present invention has the following beneficial effects:

[0016] The present invention provides the use of germacron in the preparation of products for preventing and treating post-traumatic stress disorder. The present invention has found that germacron can significantly increase the decrease in hippocampal neuron (HT22) cell viability caused by corticosterone (CORT), and reverse the reduction in nuclear area of ​​HT22 cells in an in vitro stress model, as well as the phenomenon of significant abnormalities in nuclear density, ROS level and MMP, and has a significant anti-stress injury effect. In addition, germacron can also significantly improve the PTSD-like behavior of single-pass long-term stress (SPS) mice, and improve the serum 5-HT content level and hippocampal tissue pathological abnormalities of SPS mice, and has a significant anti-PTSD effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 : Effect of germacrone on the viability of HT22 cells treated with CORT, where A is the effect of germacrone on the viability of HT22 cells; B is the effect of germacrone on the viability of HT22 cells treated with CORT; compared with the Control group, ###P<0.001; compared with the CORT group, ***P<0.001; n = 3;

[0018] Figure 2 : Effects of germacron on HT22 cell injury induced by CORT, where A is the imaging of ROS (green), MMP (red), DAPI (blue) and Merge by high-content imaging analysis system; BE is the nuclear area, nuclear density and mean fluorescence intensity of ROS and MMP of HT22 cells calculated by high-content imaging analysis system; compared with the Control group, ##P<0.01, ###P<0.001; compared with the CORT group, *P<0.05, **P<0.01, ***P<0.001; n = 3;

[0019] Figure 3: Effects of germacron on anxiety-like behavior of SPS mice, where A is the distance each group of mice entered the central area; B is the number of times each group of mice entered the central area; C is the activity trajectory of mice in OFT; D is the distance each group of mice entered the open arm area; E is the number of times each group of mice entered the open arm area; F is the activity trajectory of mice in EPMT; compared with the Control group, #P<0.05, ##P<0.01; compared with the SPS group, *P<0.05, **P<0.01; n = 8;

[0020] Figure 4 : Effects of germacron on depressive-like behaviors in SPS mice; compared with the Control group, ##P<0.01; compared with the SPS group, *P<0.05, **P<0.01; n = 8;

[0021] Figure 5 : Effects of germacron on learning and memory function of SPS mice; A is the number of times each group of mice crossed the target quadrant; B is the percentage of target quadrant visit time of each group of mice; C is the activity trajectory of mice in MWM; compared with the Control group, #P<0.05; compared with the SPS group, *P<0.05, **P<0.01; n = 8;

[0022] Figure 6 :Effects of germacron on serum 5-HT levels in SPS mice;##P<0.01 compared with the Control group;*P<0.05 compared with the SPS group; n = 6;

[0023] Figure 7 : Effects of germacron on hippocampal histopathology in SPS mice; n=3. DETAILED DESCRIPTION

[0024] The invention provides application of germacrone in preparing products for preventing and treating post-traumatic stress disorder.

[0025] In the present invention, the Germacrone (GM, molecular formula: C 15 H 22 O, molecular weight: 218.17) is a sesquiterpenoid compound (as shown in Formula 1), which is mainly extracted from Curcuma wenyujin, Curcuma guangxiensis or Curcuma pengshuo. Germacron is also a quality marker of the above-mentioned traditional Chinese medicines.

[0026]

[0027] In the present invention, the germacron can alleviate anxiety-like behaviors, depression-like behaviors and learning and memory dysfunction in mice with post-traumatic stress disorder. In the present invention, the germacron can increase the 5-HT content in serum; in the present invention, the germacron improves the abnormality of neuronal cells in hippocampal tissue. The present invention uses germacron to intervene in single-pass long-term stress (SPS) mice. Germacron can significantly improve the PTSD-like behaviors of SPS mice, and at the same time improve the serum 5-HT content level and hippocampal tissue pathological abnormalities of SPS mice, and has a significant anti-PTSD effect.

[0028] In the present invention, the germacron can inhibit HT22 cell damage; preferably, the germacron can achieve any one or more of increasing the nuclear area of ​​HT22 cells, reducing the nuclear density of HT22 cells, reducing the abnormal increase of ROS in HT22 cells, and reducing the abnormal increase of MMP in HT22 cells. The germacron of the present invention can significantly improve the decrease in HT22 cell viability caused by CORT, and reverse the reduction of the nuclear area of ​​HT22 cells in an in vitro stress model, as well as the significant abnormalities of nuclear density, ROS level and MMP, and has a significant anti-stress injury effect.

[0029] In the present invention, the product preferably includes a drug, and the active ingredient of the drug includes germacrone. In the drug of the present invention, the weight proportion of germacrone is 0.01%-99%, preferably 20%-80%, and more preferably 30%-60%. In the present invention, the drug also includes pharmaceutically acceptable excipients, and different dosage forms are prepared by adding excipients, including powders, decoctions, pills, capsules, tablets, granules and oral liquids. The present invention does not specifically limit the specific source of germacrone, and conventional commercial products in the field can be used.

[0030] In the present invention, unless otherwise specified, all raw material components are commercially available products well known to those skilled in the art.

[0031] Germacron used in the specific embodiments of the present invention was purchased from Shanghai Yuanye, B20589, HPLC ≥ 98%; HT22 cells were purchased from Shanghai QiDa Biotechnology Co., Ltd., CD0190; CORT was purchased from Shanghai Yien, R008093; CCK8 reagent was purchased from TargetMoI, C0005; reactive oxygen species detection kit was purchased from Beijing Solebao, CA1410; Mito Tracker Red CMXRos was purchased from Invitrogen, M7512; DAPI was purchased from Shanghai Biyuntian, C1005; 5-HT ELISA detection kit was purchased from Shanghai Enzyme Immunoassay, MM-0443M2.

[0032] In the specific embodiment of the present invention, the test results were analyzed using GraphPad Prism 8.0.2 statistical software. The quantitative data were expressed as one-way ANOVA for comparison among multiple groups, and T test for comparison between two groups. The difference was considered statistically significant when P < 0.05.

[0033] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0034] Example 1

[0035] Effects of Germacron on External Stress Model

[0036] a. Treatment of HT22 cells with gemacrone: HT22 cells were divided into blank control (Control) group, low-dose gemacrone (GML) group, medium-dose gemacrone (GMM) group and high-dose gemacrone (GMH) group. HT22 cells were seeded in a 96-well plate at a density of 5000 cells / well and treated with drugs: the Control group was treated with 0.1% DMSO only, the GML group, the GMM group and the GMH group were treated with 2.5μM, 5μM and 10μM gemacrone for 36h, respectively, and the volume of the solution used to treat HT22 cells in each group was 100μL.

[0037] b. In vitro stress model treated with gemacrone: HT22 cells were divided into blank control (Control) group, corticosterone (CORT) group, corticosterone + low dose of gemacrone (CORT + GML) group, corticosterone + medium dose of gemacrone (CORT + GMM) group and corticosterone + high dose of gemacrone (CORT + GMH) group. HT22 cells were seeded in 96-well plates at a density of 5000 cells / well and treated with drugs: HT22 cells in CORT + GML group, CORT + GMM group and CORT + GMH group were first pretreated with gemacrone 2.5μM, 5μM and 10μM for 12h, and then, except for the Control group, the HT22 cells in the other groups were co-incubated with 100μM CORT for 24h; the Control group was only given 0.1% DMSO, and the volume of the solution for treating HT22 cells in each group was 100μL.

[0038] 1. HT22 cell viability detection: Remove the drug-containing culture medium of HT22 cells in step a and step b, add PBS to wash the cells twice, add 100 μL CCK8 solution to each well according to the CCK8 reagent instructions (the volume ratio of CCK8 reagent: DMEM culture medium is 1:10), incubate in a 37°C cell culture incubator for 1 hour, and use Cytation5 cell imaging multifunctional microplate reader to detect the absorbance of each well at a wavelength of 450nm to calculate the cell viability of each group. The results are as follows Figure 1 shown.

[0039] Depend on Figure 1 The results showed that the CCK8 assay was used to detect the viability of HT22 cells, and there was no significant difference in the viability of HT22 cells treated with germacrone compared with the control group ( Figure 1 Figure A, P>0.05), indicating that germacron has no effect on HT22 cell viability. Neuronal cells exposed to glucocorticoids are an effective in vitro stress model. The present invention successfully established an in vitro stress model by administering 100 μM CORT to HT22 cells for 24 hours. The present invention detected the intervention effect of germacron on the in vitro stress model through CCK8 experiment. CORT acting on HT22 cells for 24 hours can lead to a significant decrease in cell viability (P<0.05), while intervention with germacron can significantly increase HT22 cell viability ( Figure 1 Figure B, P < 0.05). This indicates that germacron has a protective effect on cell viability in an in vitro stress model.

[0040] 2. Detection of ROS and MMP expression levels in HT22 cells

[0041] Discard the old culture medium in step b. According to the instructions of the reactive oxygen species detection kit, Mito Tracker Red CMXRos and DAPI, add the fluorescent probe diluted with DMEM culture medium to a 96-well plate in the dark, 100 μL per well. Incubate the cells in a 37°C cell culture incubator for 20 minutes, remove the culture medium containing the fluorescent probe, and wash the cells three times with serum-free DMEM culture medium. Subsequently, a high-content imaging analysis system was used to detect and calculate the expression of intracellular reactive oxygen species (ROS) and mitochondrial membrane potential (MMP), and the changes in the nuclear area and nuclear density of each group of cells were calculated. The results are shown in Figure 2. Figure 2 shown.

[0042] Depend on Figure 2 It can be seen that compared with the Control group, CORT can induce a significant reduction in the nuclear area of ​​HT22 cells ( Figure 2 Middle B, P<0.05), ROS level, MMP and cell nuclear density increased significantly ( Figure 2 Figure A in the middle, Figure CE, P < 0.05). Germacron intervention can significantly improve the damage of CORT to HT22 cells, which is specifically manifested as follows: compared with the CORT group, germacron significantly increased the nuclear area of ​​HT22 cells under CORT intervention; significantly reduced the abnormal increase of intracellular ROS level and MMP; and significantly reduced the nuclear density of HT22 cells. The results suggest that CORT-induced HT22 cell damage is related to abnormal ROS content and mitochondrial dysfunction, and germacron can significantly improve the ROS level and mitochondrial dysfunction of HT22 cells in the in vitro stress model.

[0043] The above results indicate that germacron can significantly improve the decrease in HT22 cell viability caused by CORT, and reverse the reduction in nuclear area of ​​HT22 cells in the in vitro stress model, as well as the significant abnormalities in nuclear density, ROS level and MMP, and has a significant anti-stress injury effect.

[0044] Example 2

[0045] Effects of Germacron on PTSD Model

[0046] 1. PTSD Model Establishment and Drug Administration

[0047] 32 male C57BL / 6J mice, 6 weeks old, weighing 20±2g (purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.), were used. The mice were adaptively raised in a standard environment for 7 days: 12h / 12h light and dark alternating lighting (8:00a.m.-20:00p.m.), the breeding temperature was controlled at 22±2℃, and the relative humidity was 50±10%. The mice were randomly divided into a blank control (Control) group, a single long-term stress (SPS) group, a single long-term stress combined with low-dose germacron (SPS+GML, 5mg / kgi.p.) group, and a single long-term stress combined with high-dose germacron (SPS+GMH, 10mg / kg ip) group, with 8 mice in each group. Except for the Control group, the remaining groups were all subjected to SPS modeling, and the modeling method is shown in Table 1:

[0048] Table 1 SPS modeling method

[0049] Stress Name method Bondage The mouse was restrained in a 50 mL centrifuge tube with an open tip prepared in advance for 2 h. Forced swimming The mouse was removed from the centrifuge tube and placed in a bucket of water with a depth of about 25 cm and a temperature of 25 ± 1 °C and forced to swim for 20 min. anaesthetization The mice were taken out of the water, rested for 15 minutes, and then exposed to anhydrous ether vapor until they lost consciousness.

[0050] After the SPS modeling was completed, the mice were returned to the cage to recover quietly. On the second day after the modeling, each group of mice was given intraperitoneal injection of medication, and the medication treatment is shown in Table 2:

[0051] Table 2 Drug administration method

[0052] Group Drug treatment Control 0.5% sodium carboxymethylcellulose solution SPS 0.5% sodium carboxymethylcellulose solution SPS+GML 0.5% sodium carboxymethylcellulose solution containing 0.5 mg / mL germacron SPS+GMH 0.5% sodium carboxymethylcellulose solution containing 1 mg / mL germacron

[0053] The drug was administered once a day with a dosing volume of 10 mL / kg for 14 consecutive days, and behavioral tests were subsequently performed on mice in each group.

[0054] 2Behavioral testing

[0055] 2.1 Open field experiment

[0056] The open field test (OFT) can be used to detect anxiety-like behavior and spatial exploration ability of mice. Before the experiment, the bottom of the open field test box (50cm×50cm×35cm) was divided into 25 squares, of which the square composed of 9 squares in the middle was defined as the central area, and the remaining squares on the periphery were defined as the surrounding area. At the beginning of the experiment, the mice were placed in the center of the white open field test box, and the activity trajectory of the mice within 5 minutes was observed and recorded by the video imaging system. After each mouse test, the open field test box was cleaned with 75% alcohol to remove the mouse's excrement and odor to avoid interference with subsequent mouse tests. Finally, the 5-minute behavioral data recorded for each mouse were analyzed, of which the first 1 minute was used as the adaptation time of the mouse, and the distance and number of times the mouse entered the central area of ​​the open field test box in the last 4 minutes were statistically analyzed.

[0057] 2.2 Elevated plus maze test

[0058] The anxiety-like behavior of mice was detected using the elevated plus maze test (EPMT). The elevated plus maze (35cm×5cm×10cm) consists of two open arms, two closed arms and a central area. At the beginning of the experiment, the mice were placed in the central area of ​​the elevated plus maze with their heads facing the open arms. The video imaging system was used to observe and record the activity trajectory of the mice within 5 minutes. After each mouse test, the elevated plus maze was cleaned with 75% alcohol to remove the mouse's excrement and odor to avoid interference with subsequent mouse tests. The 5-minute behavioral data recorded for each mouse were analyzed, of which the first 1 minute was used as the mouse's adaptation time, and the distance and number of times the mouse entered the open arm area in the last 4 minutes were statistically analyzed.

[0059] 2.3 Forced swimming test

[0060] Forced Swimming Test (FST) is a test method for evaluating depressive-like behavior in mice. In a quiet environment, mice were placed in a transparent water cylinder (30 cm × 11 cm) with about 20 cm of water in the water cylinder, and the water temperature was maintained at 25 ± 1 ° C. After each mouse test, the water in the water cylinder was replaced with clean water to remove the mouse's excrement and odor to avoid interference with subsequent mouse tests. The behavior of the mice was observed and recorded by a video imaging system for a total of 6 minutes, and the swimming immobility time of the mice in the last 4 minutes was statistically analyzed.

[0061] 2.4 Morris water maze test

[0062] The Morris water maze (MWM) test can be used to detect the spatial learning and memory ability of mice. Before the experiment, water was poured into the black water maze to a depth of about 30 cm. According to the experimental requirements, the water surface height was 2 cm below the platform / 2 cm above the platform, and the water temperature was maintained at 25±1°C. Food-grade titanium dioxide was fully dissolved in the water so that the mice could be located. The water maze was divided into four quadrants, which were defined as: Area 1, Area 2, Area 3 and Area 4. A circular transparent escape platform with a diameter of 9 cm was placed in the center of Area 1, which was defined as Area 5, also known as the "target quadrant". The specific experimental steps are as follows: (1) Platform visibility experiment: The escape platform was exposed 2 cm above the water surface and placed in Area 1. The mice were randomly placed in the pool from Area 2, Area 3 and Area 4 with their heads facing the pool wall (with icons of different shapes and colors on the wall) and allowed to swim freely for 60 seconds. If the mouse finds the escape platform within 60 s, the mouse is allowed to stay on the platform for 10 s before being taken out; if the mouse cannot find the escape platform within 60 s, the mouse is led to the platform and allowed to stay for 10 s before being taken out. (2) Positioning and navigation experiment: On the second day after the platform visual experiment, the escape platform is hidden 2 cm underwater, and the mouse is randomly placed in the pool from three directions: area 2, area 3, and area 4, with its head facing the pool wall, and allowed to swim freely for 60 s. If the mouse finds the escape platform within 60 s, the time taken is recorded as the escape latency, and the mouse is taken out after staying on the platform for 10 s. If the mouse does not find the escape platform within 60 s, it is led to the platform and allowed to stay for 10 s, and the escape latency is recorded as 60 s. This lasts for 4 days. (3) Spatial exploration experiment: After the positioning navigation experiment, the escape platform was removed and the mice were placed into the pool from area 2, area 3, and area 4 with their heads facing the pool wall. The movement trajectory of the mice and the time they stayed in the target quadrant were recorded within 60 s. The number of times the mice entered the target quadrant and the percentage of visit time within 60 s were statistically analyzed.

[0063] Behavioral test results Figure 3-Figure 5 shown.

[0064] OFT is mainly used to study the motor ability and anxiety-like behavior of mice, and EPMT is used to detect anxiety-like behavior of rodents. In order to explore the anti-PTSD effect of germacrone, the present invention uses the SPS method to construct a PTSD mouse model, and gives different doses of germacrone intervention, and uses behavioral experiments to detect the behavioral responses of each group of mice. Figure 3 As shown in Figures AC, compared with the Control group, the distance and number of times the mice in the SPS group entered the central area were significantly reduced ( Figure 3 AB, P < 0.05), showing anxiety-like behavior. At the same time, the activity trajectory of SPS mice was significantly reduced, and their spatial exploration ability was reduced ( Figure 3 EPMT results are shown in Figure C. Figure 3As shown in Figure DF, the distance and number of times that SPS mice entered the open arm area were significantly reduced compared with those of the Control group mice ( Figure 3 DE figure, P < 0.05), the activity track was significantly reduced ( Figure 3 F), showing anxiety-like behavior. After treatment with germacron, the distance and number of times that SPS mice entered the central area and the open arm area were significantly increased (P < 0.05), and the activity of SPS mice was increased, and the anxiety-like behavior of SPS mice was improved. The above results suggest that germacron has a significant improvement effect on the anxiety-like behavior of SPS mice.

[0065] FST is one of the most commonly used analytical methods for studying depressive-like behaviors in rodents. Figure 4 The results showed that compared with the control group, SPS significantly increased the immobility time of mice in FST (P < 0.05), showing depressive-like behavior. After intervention with germacron, the immobility time of SPS mice was significantly reduced, which had the effect of improving the depressive-like behavior of SPS mice.

[0066] MWM is a widely used test to assess cognitive processes in mice. Figure 5 As shown in Figure 2, compared with the Control group, the number of crossings and the percentage of visit time of the target quadrant in the SPS group mice in the spatial exploration experiment were significantly reduced ( Figure 5 Middle AB, P < 0.05). On the last day of the navigation experiment, the activity trajectories of mice were chaotic and purposeless ( Figure 5 Germacron intervention significantly increased the number of crossings and the percentage of visit time in the target quadrant of SPS mice (P < 0.05), improving the learning and memory dysfunction of SPS mice.

[0067] 3. Serum 5-HT level detection

[0068] On the second day after the mouse behavioral experiment, samples were collected and the mouse orbital blood was collected in a sterile tube, left to stand at 4°C for 30 min, and centrifuged at 3000 rpm for 15 min at 4°C. The supernatant was collected in a clean centrifuge tube and frozen at -80°C for later use.

[0069] The ELISA experiment was used to detect the level of 5-HT in mouse serum. The experimental operation was carried out according to the instructions of the mouse 5-HT enzyme-linked immunosorbent assay kit. The kit and mouse serum samples were taken out of the refrigerator in advance and equilibrated at room temperature for 1 hour before use. The detection steps are as follows:

[0070] Dilute the standard: Dilute the standard according to the instructions of the kit.

[0071] Sample addition and incubation: Set up blank wells, standard wells, and sample wells. Add 50μL of sample diluent to the blank wells; add 50μL of standard diluent to the standard wells; add 40μL of sample diluent to the sample wells, and then add 10μL of the sample to be tested. Gently shake to mix, seal the plate with a sealing film, and incubate in a 37℃ incubator for 30 minutes.

[0072] Washing: discard the reagent in the wells, spin dry, fill each well with washing solution, let it stand for 30 seconds, then discard the washing solution, repeat washing 5 times and spin dry.

[0073] Add enzyme, incubate and wash: add 50 μL of sample diluent to the blank well, add 50 μL of enzyme label reagent to the remaining wells, and then incubate in a 37°C incubator for 30 minutes. After incubation, wash in the same way as in the "washing" step.

[0074] Color development: Add 50 μL of color developer A to each well, then add 50 μL of color developer B, gently shake to mix, and then place in a 37°C incubator away from light for 10 minutes.

[0075] Termination and determination: After the color development, 50 μL of stop solution was added to each well, and the absorbance of each well at a wavelength of 450 nm was detected using the Cytation5 cell imaging multifunctional microplate reader. A standard curve was drawn based on the absorbance of the standard wells, and then the serum 5-HT content level of each group of mice was calculated based on the linear regression equation. The results are shown in Figure 2. Figure 6 shown.

[0076] The serum 5-HT level in PTSD patients is significantly lower than that in healthy people, and its level is negatively correlated with the anxiety and depression scores of patients. Figure 6 As shown in the figure, compared with the Control group, the serum 5-HT level of mice in the SPS group was significantly reduced (P < 0.05), and intervention with germacron could significantly increase the serum 5-HT level of SPS mice (P < 0.05).

[0077] 4. Analysis of Hippocampal Tissue HE Staining

[0078] After blood was drawn from the mice, brain tissue and hippocampal tissue were collected. The mouse hippocampal tissue was stored in a -80°C refrigerator for future use. The mouse brain tissue was fixed with 4% paraformaldehyde for 24 hours and then HE staining was performed.

[0079] The tissue was removed from the fixative and placed in a dehydration box, then placed in a dehydrator for dehydration and waxing according to gradient alcohol. The wax-soaked tissue was embedded and sliced ​​in an embedding machine, then dewaxed and hydrated. The slices were stained with hematoxylin for 8 minutes. Differentiate with 0.1% hydrochloric acid ethanol for 30 seconds and then wash with water. Return to blue with 0.6% ammonia water and rinse with running water. The slices were then placed in eosin stain for 3 minutes. After staining, the slices were placed in increasing gradients of ethanol and xylene in turn for dehydration and transparency. The slices were then taken out and dried naturally, and neutral gum was added to seal the slices. The slices were examined under an optical microscope to observe and collect the pathological changes in the tissue. The results are as follows Figure 7 shown.

[0080] PTSD can lead to changes in brain function and structure. The more severe the symptoms of PTSD patients, the smaller the hippocampal volume and the faster the hippocampal / parahippocampal blood flow. Figure 7 As shown in the figure, the neurons in the hippocampus of the mice in the Control group were closely arranged, with clear nuclei, rich cytoplasm, and intact structure, and no neuronal degeneration or edema was observed. The hippocampal tissue structure of the mice in the SPS group was obviously abnormal, mainly manifested as: the neurons in the CA1 region of the hippocampus were arranged disorderly and loosely, and the number was reduced; the neurons in the DG region were degenerated, and the nuclear pyknosis and deep staining were more. After the intervention of gemacrone, the cells in the CA1 region of the hippocampus of the SPS mice were arranged in an orderly manner, and the number of neurons was not reduced; the nuclear pyknosis and deep staining of neurons in the DG region were reduced.

[0081] The above results show that using germacron to intervene in SPS mice can significantly improve the PTSD-like behavior of SPS mice, while improving the serum 5-HT level and hippocampal tissue pathological abnormalities of SPS mice, and has a significant anti-PTSD effect.

[0082] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Application of germacron in the preparation of products for preventing and treating post-traumatic stress disorder.

2. The use according to claim 1, characterized in that: The germacron relieves anxiety-like behaviors, depression-like behaviors and learning and memory dysfunction caused by post-traumatic stress disorder.

3. The use according to claim 1, characterized in that: The germacron inhibits HT22 cell damage.

4. The use according to claim 3, characterized in that: The germacron can achieve any one or more of increasing the nuclear area of ​​HT22 cells, reducing the nuclear density of HT22 cells, reducing the abnormal increase of ROS in HT22 cells, and reducing the abnormal increase of MMP in HT22 cells.

5. The use according to claim 1, characterized in that: The germacron increases the 5-HT content in serum.

6. The use according to claim 1, characterized in that: The germacron improves the abnormality of neuronal cells in hippocampal tissue.

7. The use according to claim 1, characterized in that: The products include pharmaceuticals.

8. The use according to claim 7, characterized in that: The active ingredient of the drug includes germacrone.

9. The use according to claim 8, characterized in that: The weight proportion of germacrone in the medicine is 0.01%-99%.

10. The use according to claim 8, characterized in that: The drug includes pharmaceutically acceptable excipients.

Citation Information

Patent Citations

  • Application of germacrone

    CN111617060A

  • Cannabinoid formulation for oral administration

    WO2023046220A1